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Abstract
Background: HIV-testing coverage remains below the targeted 90% despite efforts and resources invested. Home-
based HIV-testing is a key approach endorsed by the World Health Organization (WHO), especially to reach
individuals who might not seek testing otherwise. Although acceptance of testing during such campaigns is high,
coverage remains low due to absent household members. This cluster-randomized trial aims to assess increase in
testing coverage using oral HIV self-testing (HIVST) among individuals who are absent or decline testing during
home-based HIV-testing.
Methods: The HOSENG (HOme-based SElf-testiNG) trial is a cluster-randomized, parallel-group, superiority trial in two
districts of Lesotho, Southern Africa. Clusters are stratified by district, village size, and village access to the nearest
health facility. Cluster eligibility criteria include: village is in catchment area of one of the study facilities, village
authority provides consent, and village has a registered, capable, and consenting village health worker (VHW). In
intervention clusters, HIV self-tests are provided for eligible household members who are absent or decline HIV-testing
in the presence of the campaign team. In control clusters, standard of care for absent and refusing individuals applies,
i.e., referral to a health facility. The primary outcome is HIV-testing coverage among individuals aged 12 years or older
within 120 days after enrollment. Secondary objectives include HIV-testing coverage among other age groups, and
uptake of the different testing modalities. Statistical analyses will be conducted and reported in line with CONSORT
guidelines. The HOSENG trial is linked to the VIBRA (Village-Based Refill of ART) trial. Together, they constitute the GET
ON (GETting tOwards Ninety) research project.
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Discussion: The HOSENG trial tests whether oral HIVST may be an add-on during door-to-door testing campaigns
towards achieving optimal testing coverage. The provision of oral self-test kits, followed up by VHWs, requires little
additional human resources, finances and logistics. If cost-effective, this approach should inform home-based HIV-
testing policies not only in Lesotho, but in similar high-prevalence settings.
Trial registration: ClinicalTrials.gov, (ID: NCT03598686). Registered on 25 July 2018. More information is available at
www.getonproject.wordpress.com.
Keywords: HIV, Cluster-randomized controlled trial, Village health worker, Community health worker, Community-
based, Self-testing, HIV-testing coverage, Lesotho, Southern Africa, Implementation research
Background
The United Nations Programme on HIV/AIDS (UNAIDS)
has shown a way forward in controlling and finally ending
the deadly acquired immune deficiency syndrome (AIDS)
epidemic by launching the 90-90-90 strategy [1]. The first
target is to ensure that 90% of all people living with hu-
man immune deficiency virus (HIV) are aware of their sta-
tus. The second target is that 90% of those diagnosed
receive sustained antiretroviral therapy (ART). And the
third target stands for 90% of those receiving ART achiev-
ing viral suppression. Globally, in 2017, progress towards
the first UNAIDS target, i.e., that 90% of people living with
HIV are aware of their status, was lower than other stages
of the HIV care cascade [2]. The most recent data from
Eastern and Southern Africa show that the percentage of
people living with HIV who know their HIV status has
steadily improved in the last few years, currently at a level
of 81% (64–95%), but still leaving a gap of approximately
1.7 million HIV-positive people to reach the target of 90%
knowing their HIV status [3, 4]. In order to reach the first
UNAIDS target, home-/community-based testing, i.e.,
HIV-testing close to where people live or work, is a key
strategy endorsed by the World Health Organization
(WHO) [5, 6]. Many studies from Southern Africa, includ-
ing Lesotho, have shown that home-based HIV-testing is
highly promising for closing the crucial gap to achieve the
first 90 [7]. Yet, it is critical to distinguish between the
principal acceptance (uptake) of HIV-testing and the HIV-
testing coverage. While in most cases the former is above
90%, the coverage often remains below 90% due to the
household members who are absent at the time of the
campaign, mainly men and young adults [8].
HIV self-testing (HIVST) has proved to be an ac-
curate diagnostic tool that increases uptake of HIV-
testing, facilitates linkage to care among target popu-
lations, and may be more cost-effective than provider-
delivered HIV-testing [9–17]. Thus, WHO strongly
endorses oral HIVST [18]. In a WHO review, 16
countries reported having a policy supportive of
HIVST, including Lesotho [19, 20].
However, to date only limited data are available, asses-
sing the effect of oral HIVST in increasing HIV-testing
coverage. This randomized controlled trial thus aims to
determine the added effect of distributing oral HIVST to
individuals absent or refusing to test during a home-
based HIV-testing campaign on HIV-testing coverage.
Methods
Setting
The HOSENG (HOme-based SElf-testiNG) trial will be
conducted in the districts of Butha-Buthe and Mokhot-
long, in Northern Lesotho, Southern Africa, in the
catchment areas of 22 health facilities. Both districts are
characterized by mostly rural settings with an estimated
population of 220,000, mainly subsistence farmers and
mine workers as well as construction or domestic la-
borers who work in neighboring South Africa. Each
district has only one mid-size town: Butha-Buthe with
approximately 25,000 inhabitants, and Mokhotlong
with approximately 10,000 inhabitants. The remaining
population lives in villages scattered over a mountain-
ous area of 5842 km2. According to the recent
household-based national survey from 2016 to 2017
the adult HIV prevalence is 17.8% in Butha-Buthe and
26.1% in Mokhotlong [21].
Design
The HOSENG trial is a cluster-randomized controlled,
superiority trial in a resource-limited setting. The ration-
ale for a cluster-randomized design at village level is (1)
the reliance of the trial on the village health workers
(VHWs) and (2) the high risk of cross-contamination
between the study arms if randomization would be done
at the individual or household level. The HOSENG trial,
with its home-based HIV-testing campaign, provides a
recruitment platform for another trial, the VIBRA
(Village-Based Refill of ART) trial [22], and thus they are
based on the same cluster-randomization and run in
parallel. Together, HOSENG and VIBRA [22] constitute
the GET ON (GETting tOwards Ninety) research
project. To ensure a balance in the exposure to the
HOSENG intervention in the two arms, the clusters
(villages) will be randomized into four potential
groups in a 1:1:1:1 allocation.
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Cluster sampling and randomization
Figure 1 summarizes the cluster sampling and
randomization process. A list of all villages with their
corresponding VHWs in the study districts was provided
by the Ministry of Health and the local District Health
Management Teams. Two local members of the research
team cross-checked the village list for accuracy. They
defined the village size (≥ 30 versus < 30 households)
and access to the nearest health facility (easy versus hard
to reach, defined by needing to cross a mountain or river
or > 10 km away from health facility) by contacting the
relevant VHW coordinators. Each village was considered
a cluster, except villages which do not have their own
VHW and, therefore, form one cluster with neighboring
villages served by the same VHW. It is not feasible to
visit all clusters (358 villages in Butha-Buthe and 290 vil-
lages in Mokhotlong) nor to include more than two
VHWs per cluster. Therefore, a random sample of 180
clusters, stratified by district, village size, and access, was
taken. If a cluster had more than two VHWs, randomly
two VHWs were selected. After excluding clusters who
did not meet the eligibility criteria (see next section), the
remaining 159 clusters were randomized into the four
groups in a 1:1:1:1 allocation ratio with block sizes of 4,
stratified by the same stratification factors. All random
sampling processes as well as the randomization were
performed by an independent statistician. The first 103
clusters will be provided to the research team and will
all be enrolled. If needed, further clusters will be re-
leased from the randomization list.
Eligibility criteria
Table 1 outlines the eligibility criteria for clusters and
households. No individual eligibility criteria apply for the
HOSENG trial as HIV-testing coverage is a population-
level outcome including every individual in the surveyed
area.
Before randomization, all VHWs from the 180 ran-
domly selected villages attend a 1-day refresher training
focusing on HIV-testing and counseling (HTC). Every
VHW takes a short pre- and post-training assessment.
The assessment includes questions about (1) HIV know-
ledge and HIV stigma using a validated questionnaire
[23], (2) HIV-testing knowledge, and (3) one open ques-
tion (“What are important qualities of a counselor?”).
The assessment will be used to evaluate the baseline
HIV/AIDS-related knowledge and stigma of the involved
VHWs and to evaluate their eligibility for participation
in the trial (Table 1).
Prior to trial start, the research team met with all rele-
vant village chief councils in order to inform them about
the trial and to obtain their consent.
Procedure
Two to three specifically trained teams, each consisting
of five to six lay-counselors, one campaign organizer and
one supervising study nurse will visit all households in
selected villages, going from door to door. The teams
will propose HTC and multi-disease screenings and pre-
vention. The population of the selected areas are in-
formed about the campaign beforehand by their village
chief. Specifically, the campaign team will arrive in the
village in the morning, meet with the village chief and
then start systematically visiting all households in the
pre-defined area by going from door to door. At the
household, the teams will proceed as follows:
1. The counselor will introduce him- or herself and
explain the purpose of the testing/screening
campaign
Fig. 1 Cluster sampling and randomization. Abbreviations: BB Butha-Buthe, MKG Mokhotlong, VHW village health worker
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2. The counselor will ask the head of household or
their representative (aged 18 years and older) for
written informed consent to the testing/screening
campaign, and to obtaining data about present and
absent household members for study purpose
a. If the head of household or the representative
refuses their household participation, the team
will leave the house, record the refusal reason,
and proceed to the next household
3. The counselor will assess the total number of
present and absent household members
a. Definition of household member: (1) is
acknowledged by the household head or the
representative as part of the household and (2)
sleeps in the household regularly (at least once a
month), and (3) if absent during the campaign:
returns to the household no later than 3 months
after the date of the home visit
4. The counselor will provide information about HIV
and testing, prevention aspects, and the other
disease screenings (see below)
5. The counselor will assess the HIV status of all
household members and screen the patient’s health
booklets (“bukana”)
6. Household members who are eligible for and
consent to testing (by filling in the Lesotho national
informed consent form for HIV-testing) undergo
HIV-testing by the counselor according to specific
cluster-arm allocation procedure and according to
national HIV-testing guidelines [20]. For absent or
declining household members the specific proce-
dures differ between the two cluster arms and are
described in detail below in the section on
intervention clusters. Figure 2 presents all possible
HIV-testing scenarios during the campaign
a. Once the HIV test is done, the counselor
documents the result in the patient’s health
booklet and provides post-test counseling. If the
HIV test is confirmed positive, the counselor
contacts the study nurse, who then provides fur-
ther counseling and assesses the participant for
enrollment into the inter-linked follow-up study
(VIBRA trial [22])
The HIV-testing campaign is combined with additional
multi-disease screening. The campaign screens for tu-
berculosis (TB) according to national guidelines using
the clinical symptom screening tool [24]. If TB is sus-
pected, one sputum sample is collected on the spot,
transported to the health facility the same day by the
campaign team for testing with GeneXpert. Another
sputum bottle for collecting a morning sample is left be-
hind, the individual is instructed on how to use it and a
follow-up plan for collection (i.e., collection by VHW) is
agreed upon. Further campaign services include alcohol
abuse screening using the CAGE questionnaire [25], infor-
mation and referral of men aged 15–50 years (HIV-nega-
tive and -positive due to stigma reasons) for voluntary
medical male circumcision (VMMC) according to WHO
recommendations [26], and promotion and provision of
male condoms. Figure 3 presents the overview of the HIV
and multi-disease campaign and its algorithm.
Intervention clusters
Figure 4 summarizes the procedures in the HOSENG
clusters and Fig. 5 the Standard Protocol Items:
Table 1 Cluster and household eligibility criteria for the HOme-based SElftestiNG (HOSENG) trial
Inclusion criteria Exclusion criteria
Cluster eligibility
1
The cluster is rural and clearly confined to the catchment area of one
of the study clinics
a. Note: 1 cluster usually consists of 1 village, but could include several
small villages if serviced by the same VHW
The village authority (= village chief) is opposed to trial participation
2
The cluster has at least 1 registered VHW who is willing to participate
and fulfills the following criteria:
a. is at least 18 years of age
b. has adequate reading and writing skills
c. successfully passes the training assessment evaluated by a local
person independent to the research project and the research team, by
checking if the VHW:
1) is able to fill in the assessment (ticking boxes, writing in correct
fields)
2) is able to give an adequate answer regarding the open question,
which implies adequate reading and writing skills and a basic logical
thinking
The VHW is not willing to attend the training or opposed to trial
participation or not fulfilling the criteria mentioned in inclusion criteria
a. Note: if a cluster entails several VHWs, then the cluster can still
participate if there is at least 1 VHW in the cluster who is willing to
participate and fulfills the criteria
Household eligibility
1
Signed informed consent from household head or representative aged
18 years or older
No signed informed consent from household head or representative
aged 18 years or older
VHW village health worker
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Recommendations for Interventional Trials (SPIRIT)
flow diagram. In the intervention clusters, the cam-
paign team will leave an oral HIVST kit (OraQuick®
ADVANCE HIV I/II, second generation serology
assay with a sensitivity of > 93%, a specificity of > 99
[27–30]) for every household member aged 12 years
or older who is absent or declined HIV-testing on
the day of the campaign. We chose 12 years as the
threshold because adolescents are an important risk
group and this is the legal age for providing HIV-
testing consent in Lesotho [24]. The household can
refuse to have an oral HIVST left behind for their
absent household members. The oral HIVST kit is
prepacked, includes a written and pictoral instruc-
tion for use in the local language, Sesotho, and the
package is labelled with a written request to consult
the VHW within 2 weeks after use of the test – irre-
spective of the result. In cases where more than one
trained VHW serves the village, the household will
be asked for the VHW of choice. The team will label
the kit with the name of the absent member before
dispensation.
One household member – the one with the closest re-
lation to the absent person(s) – will be tested and
trained using the oral HIVST. All other present house-
hold members will be tested using the standard blood-
based point-of-care HIV test according to Lesotho na-
tional guidelines [20].
The VHWs in the intervention custers will receive a
list of all household members for whom an oral HIVST
was dispensed. The VHW will visit all households 2–4
weeks after the campaign to collect the oral HIVST in
case the oral HIVST is not returned to the VHW. If an
oral HIVST is reactive, the VHW will either provide fur-
ther blood-based testing on the spot or organize referral
to the nearby health facility for confirmatory testing. All
VHWs from intervention clusters will receive a second
extensive training session about oral HIVST, handling
disclosure and stigma, and data entering on paper-based
study forms and the patient’s health booklet.
Fig. 2 HIV-testing scenarios in HOme-based SElftestiNG (HOSENG) trial. Scenarios 2 and 3 only occur in the HOSENG intervention clusters
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Control clusters
Following standard of care during home-based HIV-
testing, every absent household member or those declin-
ing HIV-testing will be encouraged to get an HIV test
done by the VHW or the nearby health facility. The re-
search team will screen the registers at the health facil-
ities in order to assess if these individuals came for
testing in the timeframe of the primary endpoint
window.
Endpoints
The primary endpoint is HIV-testing coverage among
individuals aged 12 years or older in the surveyed area
within 120 days after the home visit, defined as the pro-
portion of all individuals aged 12 years or older living in
a household of the surveyed area with a confirmed HIV
test result.
We define a confirmed HIV-negative result as either
being tested HIV-negative as per the algorithm defined
in Fig. 2, or being tested HIV-negative within the last 4
weeks with proof of documentation (i.e., documentation
in patient’s health booklets). We define a confirmed
HIV-positive result as (1) tested HIV-positive as per the
algorithm defined in Fig. 2, or (2) being tested HIV-
positive but not yet on ART with proof of documenta-
tion, or (3) being on ART with proof of documentation.
The rationale for the time point of 120 days is that we
leave oral HIVST kits at the households for all absent
household members aged 12 years or older who return
within a maximum of 3 months (see definition of house-
hold member above in the “Procedure” section). An
interval of 120 days after home visit allows sufficient
time for absent members to return to their households,
conduct self-testing, and be followed up by the VHW.
The secondary endpoints are outlined in Table 2.
Additional research within the project
For the entire GET ON project we will collect cost data,
see more details in the VIBRA trial protocol [22] pub-
lished elsewhere. Specifically, for the HOSENG trial, first,
direct costs of the intervention will be assessed: Staff costs
(campaign team, VHWs, clinic staff ), personnel training
costs (VHWs), cost of equipment (HIV tests, consum-
ables, logistics), as well as non-medical costs to the partici-
pant (i.e., cost of transportation to the ART service).
These data will provide the cost per participant achieving
Fig. 3 Algorithm of the human immune deficiency virus (HIV) and multi-disease screening/prevention campaign
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the primary endpoint within 120 days in each cluster arm
(“per participant tested cost”). Secondly, a cost-
effectiveness analysis will be performed with respect to
the primary endpoint. The cost-effectiveness ratio will be
presented as incremental cost per additional confirmed
HIV test result. Data to assess patient level costs will be
collected from a randomly selected sub-sample of study
participants from each cluster arm. Costs will be reported
in local currencies and US dollars and International
dollars. The robustness of results will be tested with prob-
abilistic sensitivity analysis and deriving cost-effectiveness
acceptability curves to capture the uncertainty around the
probability that the intervention is below the relevant
cost-effectiveness thresholds.
A nested study (ADORE study: “ADolescent ORal
sElf-testing”) will explore the effectiveness acceptability
of oral HIVST among adolescents and young adults with
quantitative methods (testing coverage among
Fig. 4 Description of the procedure in the HOme-based SElftestiNG (HOSENG) intervention and control clusters. Mobilizing: through village chief
before the campaign date, and through the campaign team on the day of the campaign by going from door to door. Further services include:
screening for tuberculosis, screening for alcohol abuse, voluntary medical male circumcision and condom provision
Fig. 5 Standard Protocol Items; Recommendations for Interventional Trials (SPIRIT) flow diagram of the HOme-based SElftestiNG (HOSENG) trial
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adolescent and young adults, defined as the proportion
of all 12–24-year-old individuals living in a household of
the surveyed area with a confirmed HIV test result) and
qualitative methods (case-control study). Cases are those
who refused testing through oral HIVST and controls
are those who accepted testing through oral HIVST. We
plan to conduct at least 10 interviews per group, strati-
fied by two pre-defined factors (male vs female; age 12–
15 years vs age 16–24 years), following the concept of
saturation. Data will be collected by a trained study
member, who was part of the HIV-testing campaign,
using a piloted interview questionnaire (KoboToolbox;
www.kobotoolbox.org), conducted in the local language
(Sesotho). Qualitative data will be recorded, transcribed,
translated into English and coded and analyzed using
the Framework Method [31].
Data collection and management
The campaign team will capture all data collected during
the campaign using a tablet-based application and plat-
form (MACRO, Elsevier). The randomization assign-
ment of the villages is pre-loaded into the program and
a unique household identifier is automatically generated.
Before leaving the household, the completed question-
naire will be checked for mistakes and completeness.
Data from the tablet devices will be uploaded regularly
via secure electronic transfer and stored on a secure ser-
ver at the Swiss Tropical and Public Health Institute
(Swiss TPH). After the follow-up period, all confidential
information of the study participants (i.e., names) will be
deleted from the database and only the anonymous
study ID will be kept. The informed consent forms will
be stored in a secure way in the headquarter of the study
center (SolidarMed Office in Butha-Buthe, Lesotho).
Participant files will be maintained in storage for a
period of at least 10 years after completion of the trial.
The VHWs enter data for following up the dispensed
oral HIVST kits on standardized paper study forms (case
report forms) that act as source documents. These data
will be collected regularly by the study team and entered
into the above-mentioned platform. A study data man-
ager will monitor data quality and completeness on a
weekly basis. Queries about the data will be sent to the
local principal investigators for follow-up and correction,
as needed. Data integrity checks will be written into the
database to limit missing fields or the entry of incorrect
data. The type of activity that an individual user in the
online study database may undertake will be regulated
by the privileges associated with their user identification
code and password.
Sample size
The sample size is driven by the VIBRA trial [22]. We
assume that to achieve the VIBRA trial [22] sample size
(minimum 262 HIV-positive individuals not on ART) by
testing about 10,000 individuals in 100 villages, based on a
previous trial [32]. According to a previous home-based
HIV-testing campaign [33], we estimate an HIV-testing
coverage rate of individuals aged 12 years or older in rural
villages of 63%. We consider a 15% increase in coverage as
relevant from a policy perspective. Using an intra-cluster
correlation (ICC) of 0.028, with a sample of 100 clusters,
we will require a sample size of 450 in order to have >
90% power to detect an increase in coverage rates to 78%
or higher. This corresponds to an increase of 1.17 (vari-
ance inflation factor (VIF)) from the 386 individuals re-
quired in the absence of clustering. If we vary the ICC for
villages and include an additional ICC for clustering at the
household level [34], the maximum VIF would be 8.3 cor-
responding to a maximum sample size of 3204 needed to
ensure 90% power to detect a 15% difference, well below
the expected 10,000 individuals to be included. Table 3
displays the sample size calculations considering all rele-
vant factors under different scenarios.
Analyses
Analyses will be reported following Consolidated Stan-
dards of Reporting Trials (CONSORT) guidelines for
cluster-randomized trials [35]. Clusters will be set as the
unit of randomization (stratified by district, size of vil-
lage, and village access to the nearest health facility),
whereas individuals are set as the unit of analysis. An
intention-to-treat set will be used, i.e., all study partici-
pants will be evaluated according to arm assignment at
randomization. The primary analysis will use multi-level
logistic regression models including village and house-
hold as random effects to assess the difference between
HIV-testing coverage in the intervention versus the
Table 2 Secondary endpoints of the HOme-based SElftestiNG (HOSENG) trial
Endpoint Definition Time point following
enrollment
1 Testing coverage
irrespective of age
Proportion of all individuals living in a household of the surveyed area with a confirmed HIV test
result
Within 120 days
2 Blood-based HIV-
testing uptake
Proportion of all present individuals living in a household of the surveyed area, being eligible for
blood-based HIV-testing and accepting to be tested using blood-based point-of-care HIV test
On the day of the
campaign
3 Oral-based HIV-testing
uptake
Proportion of all individuals living in a household of the surveyed area for whom an oral HIV self-
test (HIVST) was left behind and who performed it
Within 120 days
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control arm. These models will be adjusted for the pre-
specified randomization stratification factors and rele-
vant baseline factors (age groups, gender, education sta-
tus, employment status, HIV-testing history) that may
be randomly unbalanced between intervention and con-
trol clusters [36, 37].
Baseline characteristics will be presented according to
randomized groups; no formal testing will be performed.
Categorical variables will be described with absolute and
relative frequencies and continuous variables with me-
dians and interquartile ranges. As with the primary ana-
lysis, secondary endpoints will be analyzed with multi-
level logistic regression models including village and
household as random effects. All results will be pre-
sented as odds ratios and 95% confidence intervals. The
potential effect modification of sociodemographic deter-
minants (age groups, gender, education status, employ-
ment status, HIV-testing history) on all endpoints will
be assessed by including interaction terms in the models.
If the Wald test results for the interaction terms are sig-
nificant, intervention effects will be presented separately
by the levels of these factors. Sensitivity analyses will be
conducted in order to provide evidence that the result
seen from the primary analysis are robust. In order to
assess the reliability of the model fit, we will perform a
quadrature check. In case of unreliable model fit, we will
use generalized estimating equations to fit our model
which will provide population-averaged odds ratios and
95% confidence intervals. However, this model would
not allow inclusion of more than one random effect al-
though including the highest level of clustering is sug-
gested to be sufficient [38]. All analyses will be done
using Stata (version 14, Stata Corporation, Austin, TX,
USA). For all tests, we will use two-sided p values with
an alpha = 0.05 level of significance.
Monitoring, auditing, and data safety and monitoring
board
At least one external monitoring visit will assess adher-
ence to the approved trial protocol, accuracy of com-
pleted study forms, and the electronic dataset. The
principal investigator agrees to allow inspectors from
regulatory agencies to review records and will assist the
inspectors in their duties, if requested.
The HOSENG trial represents implementation re-
search and the oral HIVST is a well-established diagnos-
tic tool. Thus, we do not expect serious adverse effects
(SAE) on patients’ health from this intervention. How-
ever, for the purpose of this trial, we will try to capture
the following SAEs: (1) Death due to any reason (espe-
cially within 30 days of a positive HIVST results), (2)
Hospitalisation due to self-inflicted injuries within 30
days of a positive HIVST results, and (3) Hospitalisation
resulting from violent assault by others (intimate partner
violence, assault by family or community members)
within 30 days of a positive HIVST result. The campaign
team members all have several years of experience in
HTC and received an additional study-specific, 1-week
Table 3 Sample size estimations for the HOme-based SElftestiNG (HOSENG) trial
Average village size Average household size ICC (village) ICC (household) VIF Total number of clusters Total sample size
30 2 0.028 0.05 1.04 100 402
30 2 0.028 0.1 1.07 100 413
30 2 0.05 0.05 1.20 100 462
30 2 0.05 0.1 1.34 100 518
30 2 0.1 0.05 2.95 100 1139
30 2 0.1 0.1 4.4 100 1699
30 4 0.028 0.01 1.06 100 410
30 4 0.028 0.05 1.31 100 507
30 4 0.028 0.1 1.62 100 628
30 4 0.028 0.5 4.12 100 1592
30 4 0.05 0.01 1.09 100 420
30 4 0.05 0.05 1.44 100 556
30 4 0.05 0.1 1.88 100 726
30 4 0.05 0.5 5.4 100 2085
30 4 0.1 0.01 1.15 100 442
30 4 0.1 0.05 1.73 100 668
30 4 0.1 0.1 2.46 100 950
30 4 0.1 0.5 8.3 100 3204
ICC intracluster correlation coefficient, VIF variance inflation factor
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training in order to handle adverse events related to test-
ing stigma. A separate, detailed safety monitoring plan
will be developed to handle these SAEs in line with
Swiss and Basotho ethics regulations. It is not planned
to establish a data safety and monitoring board.
Discussion
HIV-testing constitutes the “front door” to reach the
UNAIDS 90-90-90 targets [39]. Currently, UNITAID
invests US$23 million into a 4-year research initiative,
called STAR, to gather evidence and catalyze the mar-
ket for HIVST, and eventually improve testing cover-
age through HIVST in three African countries
(Malawi, Zambia, and Zimbabwe) [40]. Whereas the
STAR trials assess HIVST on a large scale, the HOS-
ENG trial will focus on the use of oral HIVST during
home-based HIV-testing campaigns. As such, its re-
sult will be complementary to the findings of the
STAR project.
Home-based HIV-testing campaigns have been shown
to be very effective in achieving high testing uptake, es-
pecially in resource-limited countries [7]. However, one
major question is still unanswered: How to reach the ab-
sent people during these campaigns in a cost-effective
way? The HOSENG trial tests whether oral HIVST may
be an effective add-on during door-to-door testing cam-
paigns towards achieving optimal testing coverage. Link-
age to further testing and care after usage of oral HIVST
will be provided by the VHWs, a trusted and long-
standing public-sector cadre. VHW programs exist in all
countries of Southern Africa and are being expanded
[41]. If cost-effective, the HOSENG approach could eas-
ily be scaled up in the region, as the provision of oral
self-test kits, followed up by VHWs, requires little add-
itional human resources, finances, and logistics. The
HOSENG trial will inform home-based HTC policies
not only in Lesotho, but in similar nations in sub-
Saharan Africa. However, we will have to closely monitor
the linkage after testing and the additional burden of
work for the VHWs.
Trial status and recruitment
The trial has been launched on 26 July 2018 in both
study districts. The recruitment time is driven by the
VIBRA trial [22], as the HOSENG trial is the main re-
cruitment platform for the VIBRA trial [22]. We assume
a recruitment period of 6–8months.
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